Producer: Vermont Psychological Association
Tobacco use is common among people with mental health disorders and most are not motivated to quit in the near future. Quitting smoking is often the single best thing a patient can do for their health but tobacco treatment is often a low priority for patients with co-occurring mental health disorders. In this presentation we will review the research on tobacco treatment and harm reduction for people with co-occurring mental health disorders who are unmotivated or feel unable to quit.
Please note: if you fail to successfully complete the learning assessment quiz at the end of this video after attempting to do so 3 times, you will have to re-purchase the video in order to re-take the quiz and earn your continuing education credit.
This workshop is designed to help clinicians:
1. Describe the impact that tobacco treatment can have for people who smoke and have a co-occurring mental health disorder.
2. Utilize an empirically supported brief motivational intervention to promote quitting among patients who are unmotivated or feel unable to quit tobacco.
3. Utilize an empirically supported brief reduction-based intervention to reduce harm and promote quitting among patients who are unmotivated or feel unable to quit tobacco.
Courses sponsored by the Vermont Psychological Association are pre-approved for continuing education for psychologists by the Vermont Board of Psychological Examiners. This course qualifies for 1 continuing education credits.
Continuing education courses sponsored by the Vermont Psychological Association are pre-approved by the Vermont Office of Professional Regulation for continuing education credit for licensed independent clinical social workers in Vermont. This course provides 1 CE credits for Vermont licensing.
This course has been approved for continuing education credit by the Vermont Board of Allied Mental Health and earns 1 continuing education credits.
The New Hampshire Psychological Association is approved by the American Psychological Association to sponsor continuing education for psychologists. The New Hampshire Psychological Association maintains responsibility for this course and its content.
Completion of this course earns 1 continuing education credits. Psychologists licensed in states which approve courses sponsored by APA-approved sponsors may earn homestudy continuing education credit for taking this course.
The Vermont Psychological Association is approved by the American Psychological Association to offer continuing education for psychologists. These credits are also accepted by the New Hampshire Board of Mental Health Practice for clinical social workers licensed in New Hampshire, as provided in Mhp 402.02(b)(1). The course qualifies for 1 continuing education credits.
The Vermont Psychological Association is approved by the American Psychological Association to offer continuing education for psychologists. These credits are also accepted by the New Hampshire Board of Mental Health Practice for clinical mental health counselors licensed in New Hampshire, as provided in Mhp 402.02(b)(1). The course qualifies for mandated credit types as follows:
Ethics:
Suicide Prevention:
The Vermont Psychological Association is approved to offer continuing education to licensed clinical social workers by the Vermont Office of Professional Regulation, and is approved by the American Psychological Association to offer continuing education to psychologists. This course thus qualifies for 1 continuing education credits for Massachusetts licensed clinical social workers in Massachusetts under 258 C.M.R. §§ 31.04(2)(d), 31.04(5).
|
Presentation Slides
(2.47 MB)
Slides used by presenter during live presentation. |
36 Pages | Available after Purchase |
Dr. Klemperer is a project director at the Vermont Center on Behavior and Health and an assistant professor at the UVM Larner College of Medicine in the psychiatry department.
His research focuses on substance use and co-occurring mental illness, medications for opioid use in justice settings; nicotine use and smoking cessation treatment; and other related topics. He was recently awarded a Justice Community Opioid Innovation Network Rapid Innovation Grant from NIH to study the implementation of medications for opioid use in the justice setting.
Dr. Klemperer received his Ph.D. at the University of Vermont and did post-doctoral training at Yale University and University of Vermont. He has published numerous papers and presented his research at numerous conferences.
